Germany's Merck suffered another setback for its cancer drug Erbitux, which in a trial failed to significantly increase the length of time advanced gastric cancer patients live without their condition worsening, the pharmaceutical company said.
You are receiving this email because you subscribed to this feed at blogtrottr.com.